Sarafloxacin-d₈is intended for use as an internal standard for the quantification of sarafloxacin by GC- or LC-MS. Sarafloxacin is a fluoroquinolone antibiotic.^1,2It is active against various clinical isolates of bacteria, includingBacteroides, Fusobacterium, Eubacterium, Actinomyces, andPeptococcus(MICs = 0.5-2 µg/ml).¹Sarafloxacin inhibitsP. aeruginosaDNA gyrase.³It decreases air sac lesion severity in a chick model ofE. coli-induced colisepticemia when administered at a dose of 8 mg/kg in the drinking water 24 hours per day for five days.²Formulations containing sarafloxacin have previously been used in the treatment of bacterial infections in poultry.

1.Bansal, M.B., and Thadepalli, H.Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitroAntimicrob. Agents Chemother.31(4)619-621(1987) 2.Charleston, B., Gate, J.J., Aitken, I.A., et al.Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickensAntimicrob. Agents Chemother.42(1)83-87(1998) 3.Moir, D.T., Di, M., Opperman, T., et al.A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agentsJ. Biomol. Screen.12(6)855-864(2007)